Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-312023-04-01trueNo description of principal activitytrue00truefalse 00974145 2023-04-01 2024-03-31 00974145 2022-04-01 2023-03-31 00974145 2024-03-31 00974145 2023-03-31 00974145 c:Director1 2023-04-01 2024-03-31 00974145 d:ShareCapital 2024-03-31 00974145 d:ShareCapital 2023-03-31 00974145 d:RetainedEarningsAccumulatedLosses 2024-03-31 00974145 d:RetainedEarningsAccumulatedLosses 2023-03-31 00974145 c:EntityHasNeverTraded 2023-04-01 2024-03-31 00974145 c:FRS102 2023-04-01 2024-03-31 00974145 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 00974145 c:FullAccounts 2023-04-01 2024-03-31 00974145 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 00974145 6 2023-04-01 2024-03-31 00974145 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 00974145










CLIVEDEN BLOODSTOCK LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2024



 
CLIVEDEN BLOODSTOCK LIMITED
REGISTERED NUMBER: 00974145

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Investments
 3 
36,500
36,500

  
36,500
36,500

Current assets
  

Cash at bank and in hand
  
2,832
2,832

  
2,832
2,832

Total assets less current liabilities
  
 
 
39,332
 
 
39,332

Net assets
  
39,332
39,332


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
39,232
39,232

  
39,332
39,332


For the year ended 31 March 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



P W Freedman
Director

Date: 26 November 2024

The notes on page 2 form part of these financial statements.

Page 1

 
CLIVEDEN BLOODSTOCK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Cliveden Bloodstock Limited is a private company, limited by shares and registered in England and Wales.  
The company's registered number is 00974145 and the registered office is 2 Communications Road, Greenham Business Park, Greenham, Newbury, Berkshire, England, RG19 6AB.  
The company has not traded during the year.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

 
2.2

Valuation of investments

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Profit and Loss Account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.3

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.


3.


Fixed asset investments





Unlisted investments

£



Cost or valuation


At 1 April 2023
36,500



At 31 March 2024
36,500

Page 2